XENE Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $38.02
Market Cap (MRQ) $3.68B
P/E (TTM) -8.0
EPS (TTM) $-4.74
Revenue (TTM) $0
ROE (TTM) -43.6%
52W Range $36–$73

XENE Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

About Xenon Pharmaceuticals Inc. - Common Shares Company overview from Wikipedia

05 · wikidata
sectorHealthcare industryBiotechnology employees358 countryCA

10-Year Performance Revenue, net income, margins and EPS trends

06
Revenue$8M
2016-12-31 → 2025-12-31
EPS$-4.36
2016-12-31 → 2025-12-31
Free Cash Flow$-280M
2016-12-31 → 2025-12-31
Net margin-4612.1%
2016-12-31 → 2025-12-31
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend XENE 5Y avg Peer Median Verdict
P/E (TTM) -8.05Y avg ≈-15.4 ≈-15.4 · ·
P/S 405.65Y avg ≈275.7 ≈275.7 10.3 Overvalued
P/B (MRQ) 3.05Y avg ≈4.0 ≈4.0 3.7 Overvalued
Price / FCF (TTM) -10.95Y avg ≈-19.8 ≈-19.8 · ·
Price / Cash Flow (TTM) -10.95Y avg ≈-20.3 ≈-20.3 · ·
Price / Tangible Book 5.25Y avg ≈4.0 ≈4.0 · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise 1.1%
Next Report Nov 02, 2026
PeriodReportEPS ActualEPS EstSurprise
June 30, 2026 Aug 12, 2026 $-1.11 $-1.16 4.4%
March 31, 2026 May 12, 2026 $-1.17 $-1.21 3.1%
Dec. 31, 2025 $-1.31 $-1.22 -7.8%
Sept. 30, 2025 $-1.15 $-1.18 2.1%
June 30, 2025 $-1.07 $-1.01 -5.8%
March 31, 2025 $-0.83 $-0.93 10.8%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 16
Metric Trend 202520242023202220212020201920182017201620152014
Revenue $8M$0$0$9M$18M$32M$7M·$311.0K$2M$16M$28M
R&D Expense $301M$210M$168M$106M$75M$51M$39M$24M$26M$20M$15M$12M
SG&A Expense $80M$69M$47M$33M$22M$13M$11M$8M$7M$7M$10M$5M
Operating Expenses $381M$279M$214M$139M$97M$63M$50M$38M$33M$27M$25M$17M
Operating Income $-373M$-279M$-214M$-129M$-79M$-31M$-43M$-38M$-33M$-25M$-9M$11M
Interest Expense ·····$484.0K$1M$1M····
Interest Income $27M$42M$28M$9M$466.0K$2M$2M$1M$477.0K$504.0K$542.0K$568.0K
Other Non-op $28M$41M$31M$4M$105.0K$2M······
Pretax Income $-345M$-238M$-183M$-125M$-79M$-29M$-42M$-35M····
Income Tax $1M$-4M$-292.0K$118.0K$-6.0K$-257.0K$-23.0K$-24.0K···$0
Net Income $-346M$-234M$-182M$-125M$-79M$-29M$-42M$-34M$-31M$-23M$-16M$13M
EPS (Basic) $-4.36$-3.01$-2.73$-2.06$-1.77$-0.81·$-1.63$-1.71$-1.48$-1.10$4.11
EPS (Diluted) $-4.36$-3.01$-2.73$-2.06$-1.77$-0.81·$-1.63$-1.72$-1.48$-1.10$3.28
Shares (Basic) 79,253,75177,894,64366,889,00560,542,14243,627,45234,542,213·19,425,71117,985,06115,493,47414,281,8373,165,572
Shares (Diluted) 79,253,75177,894,64366,889,00560,542,14243,627,45234,542,213·19,425,71118,001,75915,493,47414,281,8373,963,797
EBITDA $-373M$-279M$-214M$-129M$-79M$-31M$-43M$-38M$-33M$-25M$-9M$12M
Balance Sheet 23
Metric Trend 202520242023202220212020201920182017201620152014
Cash & Equivalents $199M$143M$149M$57M$176M$45M$25M$68M$20M$17M$59M$72M
Short-term Investments $350M$484M$489M$535M$376M$132M$117M$52M$23M$47M·$12M
Receivables ·$1M$874.0K$986.0K$3M$2M$813.0K$151.0K$438.0K$200.0K$315.0K$215.0K
Prepaid Expense $10M$7M$6M$7M$4M$3M$3M$2M$716.0K$1M$2M$686.0K
Current Assets $561M$635M$645M$600M$559M$182M$145M$121M$45M$66M$61M$85M
PP&E (Net) $9M$10M$10M$6M$4M$4M$2M$991.0K$1M$1M$2M$2M
Accum. Depreciation $15M$13M$11M$9M$13M$15M$15M$16M$16M$15M$15M$14M
Total Assets $633M$798M$965M$754M$572M$189M$148M$122M$46M$67M$64M$87M
Accounts Payable $40M$34M$26M$22M$14M$11M$9M$4M$3M$4M$3M$3M
Accrued Liabilities $36M···········
Current Liabilities $42M$36M$27M$23M$14M$15M$43M$4M$4M$4M$3M$14M
Capital Leases $6M$8M$10M$10M$8M$3M$743.0K·····
Other Non-current Liabilities $3M$0··········
Total Liabilities $51M$43M$37M$33M$22M$18M$56M$19M$10M$4M$3M$15M
Long-term Debt ······$16M·$7M···
Total Debt ······$16M$15M$7M···
Common Stock $1.60B$1.46B$1.44B$1.07B$783M$398M$294M$266M$174M$173M$149M$147M
Paid-in Capital ···········$30M
Retained Earnings $-1.25B$-899M$-665M$-483M$-357M$-278M$-250M$-208M$-173M$-143M$-120M$-104M
AOCI $335.0K$-2M$-77.0K$-3M$-990.0K$-990.0K$-990.0K$-990.0K$-990.0K$-990.0K$-990.0K$-990.0K
Stockholders' Equity $582M$755M$928M$721M$550M$171M$92M$103M$36M$64M$61M$73M
Liabilities + Equity $633M$798M$965M$754M$572M$189M$148M$122M$46M$67M$64M$87M
Shares Outstanding 80,010,79076,416,08675,370,97762,587,70151,634,75235,012,12528,139,22825,750,72117,998,42017,930,59014,385,33614,181,333
Cash Flow 14
Metric Trend 202520242023202220212020201920182017201620152014
D&A $3M$3M$2M$1M$906.0K$644.0K$429.0K$586.0K$649.0K$864.0K$1M$738.0K
Stock-based Comp $54M$51M$32M$20M$10M$6M$3M$3M$2M$2M$4M$760.0K
Deferred Tax $-3M$-9M$-292.0K$-44.0K$58.0K$-285.0K$-133.0K$-105.0K····
Other Non-cash ···········$-14M
Operating Cash Flow $-279M$-181M$-151M$-101M$-70M$-48M$-5M$-35M$-29M$-20M$-18M$266.0K
CapEx $799.0K$3M$6M$3M$2M$3M$1M$507.0K$315.0K$279.0K$551.0K$2M
Investing Cash Flow $218M$165M$-111M$-293M$-247M$-17M$-66M$-29M$24M···
Stock Issued ·····$102M$27M$103M·$24M$278.0K$43M
Net Stock Activity ·····$102M$27M$103M·$24M$278.0K$43M
Financing Cash Flow $117M$12M$354M$278M$448M$86M$28M$112M$7M···
Net Change in Cash $56M$-6M$91M$-118M$131M$20M$-43M$47M$3M$-42M$-13M$34M
Taxes Paid $8M···········
Free Cash Flow $-280M$-184M$-151M$-101M$-72M$-51M$-6M$-35M$-29M$-20M$-19M$-1M
Levered FCF ·····$-51M$-7M·····
Profitability 7
Metric Trend 202520242023202220212020201920182017201620152014
Operating Margin -4974.3%··-1368.9%-428.5%-97.3%-627.0%·-10474.3%-1376.4%-60.1%39.1%
Net Margin -4612.1%··-1329.0%-427.9%-89.6%-609.1%·-9872.7%-1275.5%-101.1%45.9%
Pretax Margin -4598.6%··-1327.7%-427.9%-90.5%-609.4%·····
EBITDA Margin -4974.3%··-1368.9%-428.5%-97.3%-627.0%·-10474.3%-1376.4%-60.1%41.8%
ROA -48.3%-26.6%-21.2%-18.9%-20.7%-17.1%-30.8%-40.9%-54.0%-35.0%-20.8%18.4%
ROE -56.9%-30.2%-23.3%-17.0%-19.8%-16.3%-50.0%-32.2%-61.5%-36.8%-23.5%-465.5%
ROIC -64.3%-36.4%-23.0%-17.9%-14.4%-18.1%-39.8%·····
Liquidity & Solvency 5
Metric Trend 202520242023202220212020201920182017201620152014
Current Ratio 13.417.823.626.439.012.33.329.511.018.721.95.9
Quick Ratio 13.117.723.426.138.712.13.329.010.818.321.25.9
Debt / Equity ······0.20.10.2···
LT Debt / Equity ······0.10.10.2···
Interest Coverage ·····-64.7-29.9-27.3····
Efficiency 2
Metric Trend 202520242023202220212020201920182017201620152014
Asset Turnover 0.0··0.00.00.20.1·0.00.00.20.4
Receivables Turnover ···5.08.024.414.2·1.07.058.886.6
Per Share 5
Metric Trend 202520242023202220212020201920182017201620152014
Book Value / Share $7.27$9.88$12.31$11.53$10.65$4.89$3.27$4.01$2.00$3.56$4.24$5.13
Revenue / Share $0.09··$0.16····$0.02$0.12$1.09$7.16
Cash Flow / Share $-3.52$-2.33$-2.17$-1.63···$-1.79$-1.60$-1.26$-1.27$0.07
Cash / Share $2.49$1.87$1.97$0.91$3.40$1.29$0.88$2.63$1.14$0.95$4.08$5.08
EPS (TTM) $-4.36$-3.01$-2.73$-2.06$-1.77$-0.81$-1.87$-1.63$-1.72$-1.48$-1.10$3.28
Growth Rates 3
Metric Trend 202520242023202220212020201920182017201620152014
Revenue YoY ···-48.8%-42.7%·······
Revenue CAGR 3Y -7.4%···········
Revenue CAGR 5Y -25.3%···········
Valuation (TTM) 14
Metric Trend 202520242023202220212020201920182017201620152014
Revenue TTM $8M$0$0$9M$18M$32M$7M$311.0K$311.0K$2M$16M$28M
Net Income TTM $-346M$-234M$-182M$-125M$-79M$-29M$-42M$-34M$-31M$-23M$-16M$13M
Market Cap $3.59B$3.00B$3.47B$2.47B$1.61B$538M$369M$162M$51M$138M$116M$280M
Enterprise Value ······$243M$58M$14M···
P/E -10.3-13.0-16.9-19.1-17.6-19.0-7.0-3.9-1.6-5.2-7.36.0
P/S 478.1··261.687.516.754.0522.5163.576.67.49.9
P/B 6.24.03.73.42.93.14.01.61.42.21.93.8
P / Tangible Book 6.24.03.73.42.93.1······
P / Cash Flow -12.8-16.5-23.9-25.1-23.2-11.2-79.6-4.7-1.8-7.1-6.41052.9
P / FCF -12.8-16.2-23.0-24.4-22.5-10.6-62.8-4.6-1.8-7.0-6.2-221.8
EV / EBITDA ······-5.7-1.5-0.4···
EV / FCF ······-41.4-1.7-0.5···
EV / Revenue ······35.6187.145.0···
Earnings Yield -9.7%-7.7%-5.9%-5.2%-5.7%-5.3%-14.3%-25.8%-60.9%-19.2%-13.7%16.6%

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue $8M $0 $0 $9M $18M
Operating Margin % -4974.3% · · -1368.9% -428.5%
Net Income $-346M $-234M $-182M $-125M $-79M
Diluted EPS $-4.36 $-3.01 $-2.73 $-2.06 $-1.77

Institutional owners (13F) 331 filers · $5.9B total · As of June 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 331
Value held $5.9B
New positions 50
Exited positions 22
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
50 (-32 vs prior Q) 22 (-10 vs prior Q) 121 (-10 vs prior Q) 91 (+33 vs prior Q) -6.9M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
FMR LLC $582,353,159 9,647,998 9.95% Shares
BlackRock, Inc. $454,057,014 7,522,482 7.76% Shares
Avoro Capital Advisors LLC $348,746,620 5,777,777 5.96% Shares
Polar Capital Holdings Plc $275,878,760 4,570,556 4.72% Shares
Driehaus Capital Management LLC $266,704,101 4,418,557 4.56% Shares
JANUS HENDERSON GROUP PLC $242,858,453 4,175,982 4.15% Shares
JPMORGAN CHASE & CO $157,381,859 2,617,360 2.69% Shares
Capital International Investors $142,548,530 2,361,639 2.44% Shares
STATE STREET CORP $118,885,244 1,969,629 2.03% Shares
TWO SIGMA INVESTMENTS, LP $99,162,305 1,642,848 1.69% Shares
DEERFIELD MANAGEMENT COMPANY, L.P. $97,523,411 1,615,696 1.67% Shares
Affinity Asset Advisors, LLC $96,274,200 1,595,000 1.65% Shares
WESTFIELD CAPITAL MANAGEMENT CO LP $90,980,266 1,507,294 1.56% Shares
ALLIANCEBERNSTEIN L.P. $90,846,349 1,562,276 1.55% Shares
FRANKLIN RESOURCES INC $86,780,296 1,437,712 1.48% Shares
WELLINGTON MANAGEMENT GROUP LLP $86,042,698 1,425,492 1.47% Shares
CITADEL ADVISORS LLC $84,578,967 1,401,242 1.45% Shares
GEODE CAPITAL MANAGEMENT, LLC $82,692,689 1,370,114 1.41% Shares
Siren, L.L.C. $79,588,523 1,318,564 1.36% Shares
BNP PARIBAS ASSET MANAGEMENT Holding S.A. $77,908,522 1,290,731 1.33% Shares
Pictet Asset Management Holding SA $71,645,411 1,187,723 1.22% Shares
BRAIDWELL LP $68,294,443 1,131,452 1.17% Shares
Nuveen, LLC $59,945,086 993,126 1.02% Shares
Invesco Ltd. $54,532,726 903,458 0.93% Shares
ORBIMED ADVISORS LLC $53,869,550 892,471 0.92% Shares
Caligan Partners LP $53,717,020 889,944 0.92% Shares
AMERICAN CENTURY COMPANIES INC $53,377,571 884,319 0.91% Shares
FEDERATED HERMES, INC. $53,342,365 883,737 0.91% Shares
Capital World Investors $52,077,099 862,775 0.89% Shares
GOLDMAN SACHS GROUP INC $46,696,005 773,625 0.80% Shares
VANGUARD PORTFOLIO MANAGEMENT LLC $45,248,934 749,651 0.77% Shares
Caption Management, LLC $43,942,080 728,000 0.75% Call option
Vestal Point Capital, LP $42,252,000 700,000 0.72% Shares
Alyeska Investment Group, L.P. $42,112,689 697,692 0.72% Shares
MARSHALL WACE, LLP $41,608,683 689,342 0.71% Shares
Rock Springs Capital Management LP $41,280,627 683,907 0.71% Shares
NORTHERN TRUST CORP $40,535,724 671,566 0.69% Shares
PANAGORA ASSET MANAGEMENT INC $40,080,911 664,031 0.69% Shares
First Turn Management, LLC $36,228,072 600,200 0.62% Shares
TUDOR INVESTMENT CORP ET AL $32,919,559 545,387 0.56% Shares
LOOMIS SAYLES & CO L P $31,826,198 527,273 0.54% Shares
VANGUARD GROUP INC $29,789,210 664,641 0.51% Shares
Octagon Capital Advisors LP $29,576,400 490,000 0.51% Shares
NOVO HOLDINGS A/S $29,301,038 485,438 0.50% Shares
Candriam S.C.A. $27,905,802 462,768 0.48% Shares
Logos Global Management LP $27,162,000 450,000 0.46% Shares
Trails Edge Capital Partners, LP $26,558,400 440,000 0.45% Shares
Bank of New York Mellon Corp $25,442,801 421,518 0.43% Shares
ALGERT GLOBAL LLC $25,337,498 419,773 0.43% Shares
Aberdeen Group plc $24,671,305 408,736 0.42% Shares

Show all 331 institutional owners →

Company insiders 32 insiders · 15 officers · 16 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Ian Mortimer PRESIDENT & CEO Sept. 30, 2026 P 49,923 1 17 $-19,172,642
Thomas Patrick Kelly Chief Financial Officer Sept. 30, 2026 P 15,000 1 0 $559,800
Sherry Aulin Chief Financial Officer Dec. 18, 2024 M 0 0 0 $0
Christopher John Kenney Chief Medical Officer Aug. 28, 2026 S 2 0 4 $-670,274
Andrea Difabio Chief Legal Officer March 12, 2026 M 7,301 0 2 $-230,812
Darren S Cline Chief Commercial Officer Jan. 9, 2026 A · 0 0 $0
Christopher Von Seggern Chief Commercial Officer March 11, 2024 A 4,000 0 0 $0
James R. Empfield EVP, Drug Discovery March 11, 2024 A 10,000 0 0 $0
Sherrington Robin EVP, Strategy & Innovation March 11, 2024 A 8,398 0 0 $0
Ernesto Aycardi-Fonseca CMO March 12, 2020 A · 0 0 $0
Charles J. Cohen VP, Biology Dec. 11, 2018 M 6,550 0 0 $0
Paul Y. Goldberg SVP, Clinical Development Oct. 23, 2017 A 6,000 0 0 $0
Raymond Winquist Head, Translational Research Aug. 18, 2017 P 1,000 0 0 $0
Karen G. Corraini Gen. Counsel & Corp. Secretary March 17, 2015 A · 0 0 $0
Gary Bridger EVP, Research & Development Nov. 21, 2014 A · 0 0 $0
Dawn Svoronos Director Sept. 1, 2026 M 31,373 0 0 $0
Gillian Cannon Director June 5, 2026 S 1,455 0 1 $-63,237
Gary Patou Director June 5, 2026 S 24,896 0 1 $-70,251
Elizabeth A. Garofalo Director June 3, 2026 A 2,645 0 0 $0
Justin D. Gover Director June 3, 2026 A 2,645 0 0 $0
Patrick Machado Director June 3, 2026 A 2,645 0 0 $0
Mohammad Azab Director Dec. 19, 2023 M 74,225 0 0 $0
Simon N. Pimstone Director June 2, 2023 A 6,000 0 0 $0
Michael R Hayden Director June 3, 2021 A 116,206 0 0 $0
Frank A Holler Director May 27, 2021 M 143,653 0 0 $0
Michael M Tarnow Director May 18, 2021 M 77,942 0 0 $0
Clarissa Desjardins Director June 1, 2020 A · 0 0 $0
Richard H Scheller Director Sept. 16, 2019 A 7,000 0 0 $0
Johnston L Evans Director May 4, 2015 A 444,655 0 0 $0
Evan A. Stein Director April 30, 2015 J 4,172 0 0 $0
Associates, Llp Mx 10% owner Dec. 31, 2014 J 0 0 0 $0
Steven Gannon · Aug. 11, 2026 S 1,870 0 1 $-640,600

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 24 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
IBRN · iShares Trust 4.47% 5,685 SH Sept. 11, 2026 Daily
BBC · ETFis Series Trust I 0.81% 5,966 NS July 31, 2026 N-PORT
MEDI · Harbor ETF Trust 0.51% 3,362 NS July 31, 2026 N-PORT
IBB · iShares Trust 0.40% 694,342 SH Sept. 11, 2026 Daily
NUSC · Nushares ETF Trust 0.38% 78,317 NS July 31, 2026 N-PORT
IWO · iShares Trust 0.38% 923,340 SH Sept. 11, 2026 Daily
VTWG · VANGUARD SCOTTSDALE FUNDS 0.35% 104,976 SH Aug. 19, 2026 Daily
IBBQ · Invesco Exchange-Traded Fund Trust … 0.25% 6,839 SH Oct. 2, 2026 Daily
RSSL · Global X Funds 0.20% 46,997 NS July 31, 2026 N-PORT
IWM · iShares Trust 0.19% 2,506,283 SH Sept. 11, 2026 Daily
VTWO · VANGUARD SCOTTSDALE FUNDS 0.18% 564,724 SH Aug. 19, 2026 Daily
ESML · iShares Trust 0.17% 82,755 SH Sept. 11, 2026 Daily
ESLG · Strategy Shares 0.17% 635 NS July 31, 2026 N-PORT
FFSM · FIDELITY COVINGTON TRUST 0.12% 28,362 NS July 31, 2026 N-PORT
FHLC · FIDELITY COVINGTON TRUST 0.07% 38,542 NS July 31, 2026 N-PORT
OMFS · Invesco Exchange-Traded Self-Indexe… 0.06% 3,866 SH Oct. 2, 2026 Daily
WSML · iShares Trust 0.04% 4,898 SH Sept. 11, 2026 Daily
VFMO · VANGUARD WELLINGTON FUND 0.04% 14,319 SH Aug. 19, 2026 Daily
PDN · Invesco Exchange-Traded Fund Trust … 0.03% 2,490 SH Oct. 2, 2026 Daily
VTHR · VANGUARD SCOTTSDALE FUNDS 0.01% 8,110 SH Aug. 19, 2026 Daily
ESGV · VANGUARD WORLD FUND 0.01% 21,635 SH Aug. 19, 2026 Daily
IWV · iShares Trust 0.01% 27,091 SH Sept. 8, 2026 Daily
VT · VANGUARD INTERNATIONAL EQUITY INDEX… 0.00% 77,770 SH Aug. 19, 2026 Daily
SMMV · iShares Trust · 26,325 SH Sept. 1, 2026 Daily

XENE Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 26 analysts BUY
Median target $74.50 +95.9%
11 42.3% Strong Buy
14 53.8% Buy
1 3.8% Hold
0 0.0% Sell
0 0.0% Strong Sell

12-Month Price Target

18 analysts · 2026-10-04

Mean target $74.31 +95.5%

← Below all targets Current price $38.02
Low$46.00 Mean$74.31 High$97.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
XENE $3.59B -10.3 · -4612.1% -56.9% ·
AUPH $2.11B 7.7 20.4% 101.5% 62.7% ·
ABUS $926M -28.3 128.2% -237.9% -42.0% ·
ZYME $1.97B -24.4 38.9% -76.6% -26.9% ·
ACOG $141M -5.5 · -202.2% -43.8% ·
ENGN · · · · · ·

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed Aug 6, 2026